Clinical use of Dieletrophoresis separation for live Adipose derived stem cells
© Wu and Morrow; licensee BioMed Central Ltd. 2012
Received: 22 November 2011
Accepted: 23 February 2012
Published: 17 May 2012
Skip to main content
© Wu and Morrow; licensee BioMed Central Ltd. 2012
Received: 22 November 2011
Accepted: 23 February 2012
Published: 17 May 2012
The Expression of Concern to this article has been published in Journal of Translational Medicine 2014 12:297
Microelectrode dieletrophoresis capture of live cells has been explored in animal and cellular models ex-vivo. Currently, there is no clinical data available regarding the safety and efficacy of dielectrophoresis (DEP) buffers and microcurrent manipulation in humans, despite copious pre-clinical studies suggesting its safety. The purpose of this study was to determine if DEP isolation of SVF using minimal manipulation methods is safe and efficacious for use in humans using the hand lipotransfer model.
Autologous stromal vascular fraction cells (SVF) were obtained from lipoaspirate by collagenase digestion and centrifugation. The final mixture of live and dead cells was further processed using a custom DEP microelectrode array and microcurrent generator to isolate only live nucleated cells. Lipotransfer was completed using fat graft enhanced with either standard processed SVF (control) versus DEP filtered SVF (experimental). Spectral photography, ultrasound and biometric measurements were obtained at post operatively days 1, 4, 7, 14, 30, 60 and 90.
The DEP filter was capable of increasing SVF viability counts from 74.3 ± 2.0% to 94.7 ± 2.1%. Surrogate markers of inflammation (temperature, soft tissue swelling, pain and diminished range of motion) were more profound on the control hand. Clinical improvement in hand appearance was appreciated in both hands, though the control hand exclusively sustained late phase erosive skin breaks on post operative day 7. No skin breaks were appreciated on the DEP-SVF treated hand. Early fat engraftment failure was noted on the control hand thenar web space at 3 months post surgery.
No immediate hypersensitivity or adverse reaction was appreciated with the DEP-SVF treated hand. In fact, the control hand experienced skin disruption and mild superficial cellulitis, whereas the experimental hand did not experience this complication, suggesting a possible “protective” effect with DEP filtered SVF. Late ultrasound survey revealed larger and more frequent formation of oil cysts in the control hand, also suggesting greater risk of engraftment failure with standard lipotransfer.
Clinical DEP appears safe and efficacious for human use. The DEP microelectrode array was found to be versatile and robust in efficiently isolating live SVF cells from dead cells and cellular debris in a time sensitive clinical setting.
Automated devices for stem cell processing and isolation are of great clinical utility to the growing field of bioengineering and regenerative cellular therapy. Adipose derived stem cells (ADSC) in particular have come under greater use and scrutiny in regenerative medicine due to: relative ease of access from liposuction , abundance compared to other tissues  and lack of controversy . Heterogeneous populations of ADSCs are commonly obtained from the stromal vascular fraction (SVF) of processed adipose tissue. Currently there are commercial devices capable of isolating the SVF , however no clinical machines to date are capable of separating live versus dead cells. This becomes a particular problem for immediate clinical cellular therapy in that concomitant injection of dead cells contributes to inflammation thereby reducing odds of cell engraftment and transplantation . Moreover, cellular debris induced inflammation could pose the further threat of inhibiting normal differentiation of ADSC . Removal of dead cells could be easily achieved with tissue culture incubation and further purification steps, however, some regulatory agencies, such as the United States Food and Drug Administration, forbid the use of concomitant cell culture for cellular therapy to stay within the required limits of “minimal manipulation” for immediate clinical use .
Flow activated cytometry cell separation (FACS) or magnetic antibody cell separation (MACS) have also been proposed as a solution, yet these too are fraught with difficulties of finding FDA approved good manufacturing process (GMP) antibodies . Other technical concerns are antibody mediated activation of markers, which in some cases are actually receptors or mediators of transduction pathways affecting cell behavior . Additionally, the process further requires “washing and removing” antibodies before human use. For all the above reasons, FACS and MACS in sum are expensive, prohibitively time consuming and technically challenging beyond the scope of routine clinical practitioners. A minimally manipulated, facile, non-labeled and cost efficient method of harvesting live cells would be of tremendous value to the growing regenerative medicine field.
In simple terms this means that FDEP is related to size (πR3) and polarizability (2Re[K(w)]) of the cell, permittivity (ε1) of the suspension medium and gradient of the electric field (∇E2) applied to the device. By manipulating these parameters it is possible to either trap or repulse cells at will .
Historically DEP found initial use in the biotech industry for massive-scale tissue culture processing systems . Only recently has DEP been utilized to experimentally isolate discrete cell types such as: blood , marrow , spermatozoa , oocytes , ADSC and neuronal progenitor cells . While DEP has not been shown to detrimentally affect viability of cells in culture , DEP isolated cells have never been utilized for direct human use in any clinical application at the time of this publication. To simply assume in-vitro data can be extrapolated to human use may not be correct, since intermittent exposure to high residual electro-oxidized carbohydrates may ultimately diminish tissue engraftment and SVF function in-vivo[19, 20]. Therefore, the purpose of this study is to determine if DEP isolated SVF is comparable in safety and efficacy to conventional SVF obtained by simple centrifugation in the hand atrophy model.
Written consent was obtained for the procedure in addition to consent for enrollment into a clinical trial. Consent forms and experimental protocol were reviewed and unanimously approved by an independent IRB (FWA #A00013119). Consent and procedure was performed at a State sanctioned hospital in Mexico cleared for therapeutic autologous stem cell therapy by the Subsecretaría de Regulación y Fomento Sanitario Secretaría de Salud of the United Mexican States.
A low ionic, high carbohydrate media supplemented with antioxidants was used as manipulation buffer for the device. Conductivity was adjusted to 30 micro Sieverts and the buffer was sterile filtered (0.45 micron 43052 Corning, Corning NY). The generator was set within a frequency range from 100 to 1,000 kHz and the chamber flow rate through the filter regulated at 2 cc/min. A soak cycle of 10 minutes was allowed prior to final specimen collection. Cells were washed and centrifuged twice in sterile normal saline. Final pellet was resuspended in 2.5 cc of sterile normal saline prior to being admixed with purified fat.
To minimize risk of “wet mess” contamination, routine ice bagging for preliminary regional anesthesia was avoided in favor of skin cooling with dry ice blocks wrapped in a custom sterile thermal restrictive material, which limited cooling to 4o Celsius. All procedures, tissue and cell handling were carried out at room temperature. Infiltration and liposuction was performed using standard Klein tumescent solution with a three-hole 4 mm bullet tip cannula. Vacuum extraction was regulated at a negative pressure maximum of 350 mmHg throughout the procedure. A total of 400 cc of fat and 600 cc infranatant was obtained. Only washed fat was used for the study (infranatant was discarded). A total of 6 × 108 viable SVF cells were isolated from a 200 cc aliquot of fat, which were pelleted and resuspended in a volume of 5 cc of DEP buffer. Following DEP processing, 7 × 106 viable nucleated cells were obtained and admixed into washed, but not collagenase treated, fat for cell assisted lipotransfer.
Fat was washed in a closed sterile system using sterile normal saline serially x3. Half of the washed fat was reserved for later processing. The other half was treated with collagenase enzyme (Custom Compounding, Los Alamitos CA) to dissociate the SVF from the adipose tissue . Pelleted SVF cells were then suspended in 25 cc of normal saline, of which half was used for standard therapy and the remaining further processed using the experimental device under isolation parameters stated above. Control SVF was incubated for the same amount of time with the same amount of DEP buffer as the experimental protocol. Both control and experimental SVF were washed, centrifuged, repelleted and reconcentrated to 1 × 106 cells/mL in endotoxin free plastic ware (BT 1024, 1210; BP 1003-B Biomed Resource, Riverside CA, http://www.bmres.com). A small 100 uL aliquot sample was obtained from both SVF suspensions for cellular assays prior to being mixed back with purified non-digested fat. Fat and SVF was mixed by gentle nutation for 20 minutes prior to injection.
In a sub-experiment we evaluated the effects of saline, DEP buffer and presence of an applied electric field on SVF viability using matching time intervals and frequencies to that of the clinical protocol. The test sample aliquot was divided evenly into three sets: 1. saline control 2. DEP buffer 3. DEP buffer with applied current and 4. DEP buffer with applied current in “live capture” mode with a dead cell washout. Samples were perfused into separate but equivalent microelectrode array cartridges and eluted from the chamber using matched suspension fluids. All cells were collected and processed for Trypan blue dye exclusion. The experiment was replicated times three the same day and counted by the same observer.
Aliquots of pre- and post-DEP treated cells were analyzed by Guava-PCA flow cytometry using ViaCount(R) (Millipore 4000–0040 LOT 11–0115) reagent or monoclonal anti-human CD34 directly conjugated to phycoerythrin (R&D Systems FAB7227P LOT: ACOG01) according to manufacturer protocol. A minimum of 10,000 events were counted for each sample. Flow data was analyzed by Guava ExpressPlus software (Millipore). For CD34 expression, total counts were corrected by subtracting cells reactive to isotype control. CD34+ cells were then enumerated as a percentage of corrected total counts.
Hand atrophy correction is an experimental model well suited for this study for the following reasons: 1. two sites (left or right hand) may be used for either control or experimental treatment whereby 2. the patient functions as their own internal control and 3. minimal fat is required for harvest and processing.
One month prior to surgery patient was tested for hypersensitivity to experimental buffer with a 1.0 cc wheal beneath the skin on the antecubitum. No reaction was appreciated and anergy panel testing was negative. Enhanced fat grafts using either control SVF or DEP treated (experimental) SVF were transferred using a 2 mm blunt tip cannula with a single side port. Entry into the subdermal space was made by a single 16’ needle puncture at the wrist to allow passage of the transfer cannula. The patient and surgeon were blinded to the status (experimental vs. control) of the graft. Enhanced fat graft was distributed by serial fanning method using minimal pressure on withdrawal to deploy a thin ribbon of graft while avoiding vessels and tendinous sheaths of the hand. Over correction by 20% was performed bilaterally as this is customary standard of care. Immediate post operative photo documentation was obtained. Steri-strips® were used to close puncture sites and hands were wrapped in loose Kerlex gauze.
the patient is placed in the sitting position facing a blue/green photography wall, such that the hips are flexed at 90 degrees and knees touching the wall,
arms are fully extended directly forward to the patient
palms are placed on wall creating 45 degree angle between plane of ground and arms
inter-hand distance is to be no wider than the width between shoulders
closed with thenar at 90 degrees relative to other digits
multispectral images for detailed skin evaluation are obtained by Visia® (Canfield, Fairfield NJ), an automated photodocumentation system, with the hand in a closed fist position and touching the top reference bar.
Patient was measured for extension range of motion in her wrist and digits using specialty goniometers pre- and post-operatively, with the entire antecubetum held flush with the table. Circumference was taken at the base of each digit with a finger circumference gauge. Average circumference was calculated by taking the sum of each digit for each hand and dividing by 5. Thermocouple readings were performed on the center dorsum of the had at room temperature (Digisense® Thermocouple, Cole-Palmer, Bunker CT). Readings were obtained after 3 minutes of equilibration with the metal lead.
Case #72-001: Patient was a 69-year-old Caucasian female (BMI 29) and reformed smoker experiencing repetitive skin breaks echymosses and trauma to dorsum of hands secondary to thinning of the skin. She was also unsatisfied with the skeletonized appearance on the dorsum of her hands. Old scars (hypopigmented hyperkeratotic lesions) from inadvertent abrasions and ruptured skin from traumatic echymosses were appreciated on pre-operative evaluation. One year of routine high emollient topical skin therapy was unsuccessful. Recurrent ease of trauma began to affect her ability to carry out normal hand function and activities of daily living. Conventional dermal fillers were also offered as temporizing therapy, however, the patient reported a history (three years previous) of an adverse reaction to a dermal filler, thus a preference for autologous therapy. For this reason she requested definitive therapy with autologous fat transfer. After unblinding at the conclusion of the study (3 months following the procedure) a CA-125 (5 U/mL) and AFP (2 ng/dL) were drawn from the experimental hand and found to be negative. (Negative range for our reference laboratory is 35 U/mL for CA-125 and 10 ng/dL for AFP.)
Though current beneficial implications of accelerated healing and improved engraftment are promising, clinical DEP presents even greater future implications for the field of regenerative medicine and cell therapy. FDEP can be modulated in direction (i.e. capture vs. repulsion) and magnitude. The methodology is also versatile enough to function at the nano- , micro- and macro- level. This affords the ability to “tune-in” or “tune-out” specific cell types from the heterogenous composition of SVF, which is unprecedented and represents the development of a second generation tool for regenerative medicine.
A device, such as the one used in this study, could be used to economically select or subtract cell types to more precisely define and refine cellular therapies. For example, breast augmentation using autologous SVF enriched adipose tissue has progressed with clinical results which continue to improve [22–26], but safety issues such as calcification artifacts interfering with mammogram screening and the long-term risks of tumorgenesis have been raised . Additionally, recent epidemiologic data on prosthetic breast implants suggest foreign bodies within the breast space may be related to anaplastic large cell lymphoma (ALCL) as well . Clinical DEP could provide a safer breast fat graft by removal of osteogenic (calcification forming) precursors  or CD-30 (ALCL associated) lymphocytes, which coincidentally can occur in high abundance as a contaminant in SVF (unpublished findings). Furthermore, DEP is also capable of detecting high nuclear to cytoplasmic ratio cells and extremely small charged particles, affording the possibility of “filtering” any graft free of cancer cells [30, 31] or bacteria . DEP can even select based on cell cycle status, opening the further possibility of improving cell therapy transplantation rates by transferring only actively dividing cells .
Adipose SVF and ADSC have also found use in sports medicine, orthopedics and rehabilitation therapy. One particular treatment showing strong demand is treatment of damaged or worn cartilage with SVF/ADSC. There are conflicting reports of efficacy for this indication . Inadvertent simultaneous transplantation of pre-committed adipose precursor cells within the SVF into articular spaces could have poor long-term consequences. Recurrent damage of engrafted ectopic fat on articular surfaces release lipid and long chain fatty acids. This can be converted into prostaglandins and other mediators of inflammation (i.e. adipokines), thus accelerating native cartilage degeneration . Joint space injections with purified chondrocyte destined cells, minus adipogenic precursors, would be preferable to a random heterogeneous approach currently in use and presents yet another example of how clinical DEP could be applied.
In more recent developments, popular media reports of regenerative medicine utilization by prominent athletes (i.e. Peyton Manning, Chad Ochocinco and Terrell Owens) have created a glamorizing effect to the field. While these famous cases of stem cell therapy are helpful in raising awareness, disproportionate attention to the promise, but not the potential consequences, leave serious concerns of the public being unfairly biased and indirectly counseled by dominating modern media and content . Though it is not the intention of this paper to morally assail any practitioner or patient, we believe the growing demand for cellular therapies is reaching critical mass and signifies the necessity of a clinical paradigm shift from a focus of efficacy, to one of safety. To this end, all second generation separation technologies, especially DEP, should be investigated with a greater sense of urgency to address the growing immediate need for safety.
Though only one human subject was used for this pilot study, five independent injections were performed for each hand web space and no long-term sonographic irregularities (hyperechoic or hypoechoic) were appreciated with DEP processing. Clinical DEP processing of SVF cells, therefore, appears to be feasible and safe for use in humans, and confers an improved healing and engraftment capability in comparison to standard SVF in the hand lipotransfer model. Use of DEP in the clinical setting offers the promise of a potentially more safe, rational and personalized approach to cellular therapeutics.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.